Lincoln Pharmaceuticals Ltd Share Price

620.6
(-0.24%)
Jul 23, 2024|03:32:38 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open616
  • Day's High622.95
  • 52 Wk High755.15
  • Prev. Close622.1
  • Day's Low604.9
  • 52 Wk Low397
  • Turnover (lac)254.49
  • P/E13.34
  • Face Value10
  • Book Value297.45
  • EPS46.58
  • Mkt. Cap (Cr.)1,243.04
  • Div. Yield0.29
No Records Found

Lincoln Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

616

Prev. Close

622.1

Turnover(Lac.)

254.49

Day's High

622.95

Day's Low

604.9

52 Week's High

755.15

52 Week's Low

397

Book Value

297.45

Face Value

10

Mkt Cap (₹ Cr.)

1,243.04

P/E

13.34

EPS

46.58

Divi. Yield

0.29

Lincoln Pharmaceuticals Ltd Corporate Action

26 Aug 2023

12:00 AM

AGM

Announcement Date: 26 Aug, 2023

arrow

28 Aug 2023

12:00 AM

BookCloser

arrow

8 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

25 May 2023

12:00 AM

Dividend

Dividend Amount: 1.5

arrow

Lincoln Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Lincoln Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

23 Jul, 2024|02:22 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 49.77%

Foreign: 0.00%

Indian: 49.77%

Non-Promoter- 3.98%

Institutions: 3.98%

Non-Institutions: 46.23%

Custodian: 0.00%

Share Price

Lincoln Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

20.03

20.03

20.03

20

Preference Capital

0

0

0

0

Reserves

482.44

412.85

346.36

284.49

Net Worth

502.47

432.88

366.39

304.49

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Revenue

376.08

324.95

304.27

310.81

yoy growth (%)

15.73

6.79

-2.1

39.21

Raw materials

-186.77

-171.16

-172.67

-203.65

As % of sales

49.66

52.67

56.74

65.52

Employee costs

-54.89

-47.5

-35.05

-26.73

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Profit before tax

64.04

43.09

35.74

30.05

Depreciation

-5.46

-4.39

-3.85

-3.21

Tax paid

-14.48

-10.34

-8.33

-8.31

Working capital

-8.51

25.15

13.34

-4.84

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2020Mar-2018Mar-2017Mar-2016

Growth matrix (%)

Revenue growth

15.73

6.79

-2.1

39.21

Op profit growth

29.17

8

30.85

40.73

EBIT growth

39.41

15.08

15.61

39.5

Net profit growth

51.3

19.53

26.01

47.2

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

580.55

510.31

472.12

424.19

386.49

Excise Duty

0

0

0

0

0

Net Sales

580.55

510.31

472.12

424.19

386.49

Other Operating Income

0

0

0

0

0

Other Income

34.42

22.47

10

5.66

11.04

Lincoln Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,587.35

124.833,80,990.4867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,534.8

76.421,20,383.365310.662,259507.93

Cipla Ltd

CIPLA

1,490

32.381,20,295.961,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,154.55

33.791,16,159.651,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,770.9

26.361,12,931.21,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lincoln Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman (Non-Executive)

Kishorbhai M Shah

Managing Director

Mahendra G Patel

Whole-time Director

Hasmukhbhai I Patel

Independent Director

Pirabhai R Suthar

Whole-time Director

Munjal Mahendrabhai Patel

Whole-time Director

Aashish R Patel

Independent Director

Meha Patel

Independent Director

Saurin J Parikh

Director

Rajnikant G Patel

Whole-time Director

Anand Arvindbhai Patel

Company Sec. & Compli. Officer

Trusha Shah

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in Jan 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The company was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.96 to part-finance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 2021-22, Lincoln Parenteral Limited (Transferor Company), an er
Read More

Company FAQs

What is the Lincoln Pharmaceuticals Ltd share price today?

Down Arrow

The Lincoln Pharmaceuticals Ltd shares price on N/A is Rs.₹624.25 today.

What is the Market Cap of Lincoln Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lincoln Pharmaceuticals Ltd is ₹1250.36 Cr. as of 23 Jul ‘24

What is the PE and PB ratio of Lincoln Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Lincoln Pharmaceuticals Ltd is 13.34 and 2.10 as of 23 Jul ‘24

What is the 52 Week High and Low of Lincoln Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Lincoln Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lincoln Pharmaceuticals Ltd is ₹397.85 and ₹754.25 as of 23 Jul ‘24

What is the CAGR of Lincoln Pharmaceuticals Ltd?

Down Arrow

Lincoln Pharmaceuticals Ltd's CAGR for 5 Years at 34.24%, 3 Years at 18.85%, 1 Year at 52.55%, 6 Month at -6.20%, 3 Month at 4.86% and 1 Month at 1.20%.

What is the shareholding pattern of Lincoln Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Lincoln Pharmaceuticals Ltd is as follows:
Promoters - 49.78 %
Institutions - 3.99 %
Public - 46.24 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.